Eli Lilly’s experimental weight-loss pill delivered a 12.4 per cent body weight reduction in patients over 72 weeks, the pharmaceutical giant announced on Thursday.
However, the late-stage study results fell short of Novo Nordisk’s injectable Wegovy, which delivered 14.9 per cent weight loss over 68 weeks in a 2021 trial.